Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb

Immatics N.V., a clinical-stage biopharmaceutical company, has announced that Bristol Myers Squibb (BMS) will be investing $35 million in the company. BMS acquired 2,419,818 ordinary shares of Immatics through a private placement transaction at a price of $14.461 per share. As part of the investment, BMS also gained the right to appoint a member to the Immatics Scientific Advisory Board. Harpree..